FCCC LOGO Faculty Publications
Kuban DA , Tucker SL , Dong L , Starkschall G , Huang EE , Cheung MR , Lee AK , Pollack A
Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer
International Journal of Radiation Oncology Biology Physics. 2008 Jan;70(1) :67-74
PMID: ISI:000251867700009   
Back to previous list
Abstract
Purpose: To report the long-term results of a randomized radiotherapy dose escalation trial for prostate cancer. Methods and Materials: From 1993 to 1998, a total of 301 patients with stage T1b to T3 prostate cancer were accrued to a randomized external beam dose escalation trial using 70 Gy versus 78 Gy. The median follow-up is now 8.7 years. Kaplan-Meier analysis was used to compute rates of prostate-specific antigen (PSA) failure (nadir + 2), clinical failure, distant metastasis, disease-specific, and overall survival as well as complication rates at 8 years post-treatment. Results: For all patients, freedom from biochemical or clinical failure (FFF) was superior for the 78-Gy arm, 78%, as compared with 59% for the 70-Gy arm (p = 0.004, and an even greater benefit was seen in patients with initial PSA > 10 ng/ml (78% vs. 39%, p = 0.001). The clinical failure rate was significantly reduced in the 78-Gy arm as well (7% vs. 15%, p = 0.014). Twice as many patients either died of prostate cancer or are currently alive with cancer in the 70-Gy arm. Gastrointestinal toxicity of grade 2 or greater occurred twice as often in the high dose patients (26% vs. 13%), although genitourinary toxicity of grade 2 or greater was less (13% vs. 8%) and not statistically significantly different. Dose-volume histogram analysis showed that the complication rate could be significantly decreased by reducing the amount of treated rectum. Conclusions: Modest escalation in radiotherapy dose improved freedom from biochemical and clinical progression with the largest benefit in prostate cancer patients with PSA > 10 ng/ml. (c) 2008 Elsevier Inc.
Notes
ISI Document Delivery No.: 244LP Times Cited: 0 Cited Reference Count: 25 Cited References: *AM JOINT COMM CAN, 1992, AJCC CANC STAG MAN COX JD, 1995, INT J RADIAT ONCOL, V31, P1341 COX JD, 1997, INT J RADIAT ONCOL, V37, P1035 DAMICO AV, 2003, J UROLOGY 2, V170, S42 DAMICO AV, 2003, J UROLOGY, V170, S46 DAMICO AV, 2004, JAMA-J AM MED ASSOC, V292, P821 HANKS GE, 1988, INT J RADIAT ONCOL, V15, P1299 HANLON AL, 1997, INT J RADIAT ONCOL, V38, P59 HUANG EH, 2002, INT J RADIAT ONCOL, V54, P1314 PAVY JJ, 1995, INT J RADIAT ONCOL, V31, P1043 PEETERS STH, 2006, J CLIN ONCOL, V24, P1990 POLLACK A, 2000, INT J RADIAT ONCOL, V48, P507 POLLACK A, 2000, J CLIN ONCOL, V18, P3904 POLLACK A, 2002, INT J RADIAT ONCOL, V53, P1097 POLLACK A, 2002, INT J RADIAT ONCOL, V54, P677 ROACH M, 2006, INT J RADIAT ONCOL, V65, P965 SCARDINO P, 2005, J NATL COMPR CANC S1, V3, S29 SHIPLEY WU, 1995, INT J RADIAT ONCOL, V32, P3 STOREY MR, 2000, INT J RADIAT ONCOL, V48, P635 TUCKER SL, 2004, INT J RADIAT ONCOL, V59, P353 TUCKER SL, 2004, INT J RADIAT ONCOL, V60, P1589 VANCE W, 2007, INT J RADIAT ONCOL, V67, P828 ZELEFSKY MJ, 2001, J UROLOGY, V166, P876 ZELEFSKY MJ, 2006, J UROLOGY 1, V176, P1415 ZIETMAN AL, 2005, JAMA-J AM MED ASSOC, V294, P1233 Kuban, Deborah A. Tucker, Susan L. Dong, Lei Starkschall, George Huang, Eugene E. Cheung, M. Rex Lee, Andrew K. Pollack, Alan ELSEVIER SCIENCE INC; 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA